preclinical model raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-10 and is reviewed periodically as new material appears.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
From the mid-1960s onward, Ramachandran continued studying crystallography, including the conformation of peptides including types of β-turns, conformation of prolyl residues, cis-peptide units, occurrence and need for non-planarity of the peptides, NMR coupling constants and peptides containing L and D residues, among other tops. He was awarded the prestigious Jawarharlal Nehru Fellowship in 1968 for research on Protein and Polypeptide Conformation; he was one of its first recipients. Ramachandran can be credited for bringing together into the one field of molecular biophysics the then disparate fields of X-ray crystallography, peptide synthesis, NMR and other optical studies, and physico-chemical experimentation. In 1970, he founded the Molecular Biophysics Unit at the Indian Institute of Science which was later known as the Centre of Advanced Study in Biophysics. Ramachandran and A.V. Lakshminarayanan developed convolution-backprojection algorithms which greatly improved the quality and practicality of results obtainable by x-ray tomography. Compared to previously used methods, their algorithms considerably reduced computer processing time for image reconstruction, as well as providing more numerically accurate images. As a result, commercial manufacturers of x-ray tomographic scanners started building systems capable of reconstructing high resolution images that were almost photographically perfect. In 1971, they published their research in PNAS. In 1981, Ramachandran became a founding member of the World Cultural Council.
Rapidly progressive glomerulonephritis, also known as crescentic GN, is characterised by a rapid, progressive deterioration in kidney function. People with rapidly progressive glomerulonephritis may present with a nephritic syndrome. In management, steroid therapy is sometimes used, although the prognosis remains poor. Three main subtypes are recognised:
Naturally occurring platinum (78Pt) consists of five stable isotopes (192Pt, 194Pt, 195Pt, 196Pt, 198Pt) and one long-lived (half-life 4.83×1011 years) radioisotope (190Pt). There are also 34 known synthetic radioisotopes ranging from 165Pt to 204Pt, and longest-lived of those is 193Pt with a half-life of 50 years. All the others have half-lives under two weeks, most under a day. There are numerous metastable states, of which the most stable are 193mPt and 195mPt with half-lives 4.33 and 4.010 days, decaying to their ground states. Despite the obstacles to measurement with rare isotopes of rare elements, with a very slow decay, the 190Pt/186Os system has been used in isotope geology, though not directly for dating. All isotopes of platinum are either radioactive or observationally stable, meaning that they are predicted to be radioactive but no actual decay has been observed. Platinum-195 is the most abundant isotope, making platinum one of the only three elements to have its most abundant isotope with an odd neutron number (the other two being beryllium and nitrogen); however, it is so only by a small margin, unlike the other two, and is more in the nature of a coincidence.
However, several academic researchers became concerned that AI was no longer pursuing its original goal of creating versatile, fully intelligent machines. Beginning around 2002, they founded the subfield of artificial general intelligence (or "AGI"), which had several well-funded institutions by the 2010s. Deep learning began to dominate industry benchmarks in 2012 and was adopted throughout the field. For many specific tasks, other methods were abandoned. Deep learning's success was based on both hardware improvements (faster computers, graphics processing units, cloud computing) and access to large amounts of data (including curated datasets, such as ImageNet). Neural-network approaches also advanced natural language processing. In 2013, word2vec introduced efficient methods for learning distributed word representations. In 2014–2015, sequence-to-sequence and attention mechanisms advanced neural machine translation. Deep learning's success led to an enormous increase in interest and funding in AI. The amount of machine learning research (measured by total publications) increased by 50% in the years 2015–2019.
Sources: en.wikipedia.org
CaSO4 · 1/2 H2O + 1+1/2 H2O → CaSO4 · 2 H2O This reaction is exothermic and is responsible for the ease with which gypsum can be cast into various shapes including sheets (for drywall), sticks (for blackboard chalk), and molds (to immobilize broken bones, or for metal casting). Mixed with polymers, it has been used as a bone repair cement. Small amounts of calcined gypsum are added to earth to create strong structures directly from cast earth, an alternative to adobe (which loses its strength when wet). The conditions of dehydration can be changed to adjust the porosity of the hemihydrate, resulting in the so-called α- and β-hemihydrates (which are more or less chemically identical). On heating to 180 °C (356 °F), the nearly water-free form, called γ-anhydrite (CaSO4·nH2O where n = 0 to 0.05) is produced. γ-Anhydrite slowly reabsorbs water to return to the dihydrate state, a property exploited in some commercial desiccants. On heating above 250 °C, the completely anhydrous form called β-anhydrite or "natural" anhydrite is formed. Natural anhydrite does not absorb water, even over geological timescales, unless very finely ground. The variable composition of the hemihydrate and γ-anhydrite, and their easy inter-conversion, is due to their nearly identical crystal structures containing "channels" that can accommodate variable amounts of water, or other small molecules such as methanol.
Robinson and another colleague, Pauling founded the Institute of Orthomolecular Medicine in Menlo Park, California, which was soon renamed the Linus Pauling Institute of Science and Medicine. Pauling directed research on vitamin C, but also continued his theoretical work in chemistry and physics until his death. In his last years, he became especially interested in the possible role of vitamin C in preventing atherosclerosis and published three case reports on the use of lysine and vitamin C to relieve angina pectoris. During the 1990s, Pauling put forward a comprehensive plan for the treatment of heart disease using lysine and vitamin C. In 1996, a website was created expounding Pauling's treatment which it referred to as Pauling Therapy. Proponents of Pauling Therapy believe that heart disease can be treated and even cured using only lysine and Vitamin C and without drugs or heart operations. Pauling's work on vitamin C in his later years generated much controversy. He was first introduced to the concept of high-dose vitamin C by biochemist Irwin Stone in 1966. After becoming convinced of its worth, Pauling took 3 grams of vitamin C every day to prevent colds. Excited by his own perceived results, he researched the clinical literature and published Vitamin C and the Common Cold in 1970. He began a long clinical collaboration with the British cancer surgeon Ewan Cameron in 1971 on the use of intravenous and oral vitamin C as cancer therapy for terminal patients.
When compared to patients with type 2 diabetes, MODY patients are often more sensitive to sulphonylureas, such that a lower dose should be used to initiate treatment to avoid hypoglycaemia. Patients with MODY less often suffer from obesity and insulin resistance than those with ordinary type 2 diabetes (for whom insulin sensitizers like metformin or the thiazolidinediones are often preferred over the sulfonylureas).
=== Business === Protein Capture Science is a biotech start-up company commercializing a self-removing affinity tag technology for research and large-scale purifications of proteins. Wood and Izabela Gierach are co-founders of the company, based in Columbus, Ohio. The first line of the iCapTag products for protein purification was showcased in the Industry Innovators 2021-2022 Issue of the journal BioProcess International. Protein Capture Science was recently awarded several grants and funding, including highly competitive The Ohio Third Frontier Technology Validation and Start-Up Fund and the Concept Fund for extraordinary technologies by the Department of Development, State of Ohio.
Over a ten-year period between 1988 and 1998 Channon developed a high performance radio controlled helicopter suitable for a variety of professional uses including surveillance, environmental monitoring and aerial photography. Nitrohawk was equipped with a broadcast quality digital camera with pan/tilt and 20x zoom. A novel gyroscopic stabilization system designed by Channon allowed the vehicle to hover in place without constant attention by the pilot, and allowing high resolution images to be captured or transmitted live without motion blur; performance that was state of the art in the mid-1990s. A Nitrohawk was acquired to assist with stunt filming in the movie Skyfall. Animal warning system for road vehicles In 1999 Channon developed an ultrasonic device that can be attached to road vehicles, with the aim of cutting the number of wild animals killed on roads. Channon noticed that while driving across Exmoor in his turbo charged car he didn't hit any animals at all until one occasion when his car's turbo charger failed. He deduced that the high-pitched whine of the turbo charger must be giving an early warning to animals and reproduced the same effect with a simple ultrasonic device.
Sources: en.wikipedia.org
The enzyme was incorrectly classified as acting on a CH-OH group EC 1.1.3.23: Thiamine oxidase EC 1.1.3.24: L-galactonolactone oxidase EC 1.1.3.25: Now included with EC 1.1.99.18, cellobiose dehydrogenase (acceptor) EC 1.1.3.26: Now EC 1.21.3.2, columbamine oxidase EC 1.1.3.27: hydroxyphytanate oxidase EC 1.1.3.28: nucleoside oxidase EC 1.1.3.29: N-acylhexosamine oxidase EC 1.1.3.30: polyvinyl-alcohol oxidase EC 1.1.3.31: deleted, cannot be distinguished from EC 1.1.3.13, alcohol oxidase EC 1.1.3.32: Now EC 1.14.21.1, (S)-stylopine synthase EC 1.1.3.33: Now EC 1.14.21.2, (S)-cheilanthifoline synthase EC 1.1.3.34: Now EC 1.14.21.3, berbamunine synthase EC 1.1.3.35: Now EC 1.14.21.4, salutaridine synthase EC 1.1.3.36: Now EC 1.14.21.5, (S)-canadine synthase EC 1.1.3.37: D-arabinono-1,4-lactone oxidase EC 1.1.3.38: vanillyl-alcohol oxidase EC 1.1.3.39: nucleoside oxidase (H2O2-forming) EC 1.1.3.40: D-mannitol oxidase EC 1.1.3.41: xylitol oxidase EC 1.1.3.42: prosolanapyrone-II oxidase EC 1.1.3.43: paromamine 6′-oxidase EC 1.1.3.44: 6′′′-hydroxyneomycin C oxidase EC 1.1.3.45: aclacinomycin-N oxidase EC 1.1.3.46: 4-hydroxymandelate oxidase EC 1.1.3.47: 5-(hydroxymethyl)furfural oxidase EC 1.1.3.48: 3-deoxy-α-D-manno-octulosonate 8-oxidase EC 1.1.3.49: (R)-mandelonitrile oxidase
The top-down approach is breaking down of a system into small components, while bottom-up is assembling sub-systems into a larger system. A bottom-up approach for nano-assembly is a primary research target for nano-fabrication because top down synthesis is expensive (requiring external work) and is not selective on very small length scales, but is currently the primary mode of industrial fabrication. Generally, the maximum resolution of the top-down products is much coarser than those of bottom-up; therefore, an accessible strategy to bridge "bottom-up" and "top-down", is realizable by the principles of self-assembly. By controlling local intermolecular forces to find the lowest-energy configuration, self-assembly can be guided by templates to generate similar structures to those currently fabricated by top-down approaches. This so-called bridging will enable fabrication of materials with the fine resolution of bottom-up methods and the larger range and arbitrary structure of top-down processes. Furthermore, in some cases components are too small for top-down synthesis, so self-assembly principles are required to realize these novel structures. Classification Nanostructures can be organized into groups based on their size, function, and structure; this organization is useful to define the potential of the field. By size Among the more sophisticated and structurally complex nanostructures currently available are organic macromolecules, wherein their assembly relies on the placement of atoms into molecular or extended structures with atomic-level precision.
Sorenson, MD, from the Mayo Clinic in Rochester, Minnesota "While this is very disappointing, at least it was definitive and gives, I think, a pretty definitive answer, at least for this strategy for this drug," Dr. Sorenson said. However, he added, "there is still a great deal of evidence that the IGF-1 pathway can be beneficial to people who have ALS, but just not the way we administered it." Novel methods of delivering IGF-1 in a more selected fashion are now under way, including the use of viral mediators or stem cells. Two previous phase 3 trials of IGF-1 in ALS showed inconsistent results: 1 trial, carried out in North America, did find a benefit, whereas the other, a European trial, did not confirm the earlier findings. "The results of our study most resemble those of the previous European study, with no benefit in either survival or functional scales", De Sorenson concludes. "It is disappointing that we were unable to confirm the benefit that was noted in the previous North American study." Conclusive evidence points, what Iplex (and any form of IGF-1) can't slow progression in human ALS. Lot of sites that have published articles about the link between Lyme disease and ALS are sponsored by clinics specializing in the treatment of chronic Lyme disease, or by the sellers of products for treating this, or both.
== Further reading == Budd, A. (2012). "Introduction to Genome Biology: Features, Processes, and Structures". Evolutionary Genomics. Methods in Molecular Biology. Vol. 855. pp. 3–4. doi:10.1007/978-1-61779-582-4_1. ISBN 978-1-61779-581-7. PMID 22407704.
They include reverse transcriptase, which is a viral enzyme involved in the infection of cells by retroviruses, and telomerase, which is required for the replication of telomeres. For example, HIV reverse transcriptase is an enzyme for AIDS virus replication. Telomerase is an unusual polymerase because it contains its own RNA template as part of its structure. It synthesizes telomeres at the ends of chromosomes. Telomeres prevent fusion of the ends of neighboring chromosomes and protect chromosome ends from damage. Transcription is carried out by a DNA-dependent RNA polymerase that copies the sequence of a DNA strand into RNA. To begin transcribing a gene, the RNA polymerase binds to a sequence of DNA called a promoter and separates the DNA strands. It then copies the gene sequence into a messenger RNA transcript until it reaches a region of DNA called the terminator, where it halts and detaches from the DNA. As with human DNA-dependent DNA polymerases, RNA polymerase II, the enzyme that transcribes most of the genes in the human genome, operates as part of a large protein complex with multiple regulatory and accessory subunits.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.